文献速递肝病消化道肿瘤与早癌

不同病因肝硬化患者的肝细胞癌风险:一项基于人群的队列研究

Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-01

该研究基于英国全科医学研究数据库(1987-2006)识别3107例肝硬化患者,链接国家癌症登记(1971-2006)获取肝细胞癌诊断,采用Cox比例风险回归估计风险比,并考虑竞争风险预测10年累积发病率。病毒性与自身免疫/代谢性病因肝硬化患者肝细胞癌调整相对风险较酒精性肝硬化升高2至3倍;10年预测累积发病率酒精性1.2%、慢性病毒性肝炎4.0%、自身免疫或代谢性疾病3.2%、隐源性1.1%。结论认为肝硬化患者10年肝细胞癌累积发病率估计为4%或更低,且因病因而异,酒精性或隐源性肝硬化风险最低。

要点

  • 病毒性及自身免疫/代谢性病因肝硬化患者肝细胞癌调整相对风险较酒精性肝硬化升高2至3倍。
  • 10年预测累积发病率:酒精性1.2%、慢性病毒性肝炎4.0%、自身免疫或代谢性疾病3.2%、隐源性1.1%。
  • 肝硬化患者10年肝细胞癌累积发病率估计为4%或更低,且因病因而异。

核心结论

  • 在英国基于人群的研究中,肝硬化患者10年肝细胞癌累积发病率估计为4%或更低,且因病因而异,酒精性或隐源性肝硬化患者风险最低。

研究设计与样本

  • 基于人群的队列研究,从英国全科医学研究数据库(1987-2006)识别3107例肝硬化患者,肝细胞癌诊断来自链接的国家癌症登记(1971-2006),采用Cox比例风险回归估计风险比,并考虑全因死亡和肝移植竞争风险预测10年累积发病率。

主要发现

  • 在3107例肝硬化患者中,病毒性和自身免疫/代谢性病因患者肝细胞癌调整相对风险较酒精性肝硬化患者升高2至3倍。
  • 10年预测累积肝细胞癌发病率:酒精性1.2%、慢性病毒性肝炎4.0%、自身免疫或代谢性疾病3.2%、隐源性1.1%。

关键数值与推荐

  • 病毒性和自身免疫/代谢性病因肝硬化患者肝细胞癌调整相对风险较酒精性肝硬化升高2至3倍。
  • 10年预测累积肝细胞癌发病率:酒精性1.2%、慢性病毒性肝炎4.0%、自身免疫或代谢性疾病3.2%、隐源性1.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Among patients with cirrhosis, only those determined to be at risk for hepatocellular carcinoma (HCC) should undergo surveillance. However, little is known about how different aetiologies of cirrhosis affect risk for HCC. AIM: To quantify the cumulative incidence of HCC among a representative population of people with cirrhosis of the liver of varying aetiology. METHODS: We identified subjects with hepatic cirrhosis from the UK's General Practice Research Database (1987-2006). Diagnoses of HCC were obtained from linked national cancer registries (1971-2006). Cox proportional hazards regression was used to estimate hazard ratios. The predicted 10-year cumulative incidence of HCC for each aetiology of cirrhosis was estimated while accounting for competing risks of death from any cause and liver transplant. RESULTS: Among 3107 people with cirrhosis, the adjusted relative risk of HCC was increased twofold to threefold among people with viral and autoimmune/metabolic aetiologies, compared to those with alcohol-associated cirrhosis. The 10-year predicted cumulative incidence estimates of HCC for each aetiology were alcohol, 1.2%; chronic viral hepatitis, 4.0%; autoimmune or metabolic disease, 3.2%; and cryptogenic, 1.1%. CONCLUSIONS: In a population-based study in the UK, people with cirrhosis have an estimated cumulative 10-year incidence of HCC of 4% or lower. Cumulative incidence varies with aetiology such that individuals with alcohol or cryptogenic cirrhosis have the lowest risk for HCC. These findings provide important information for cost-effectiveness analyses of HCC surveillance.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. West J, Card TR, Aithal GP, et al. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther. 2017. PMID: 28144999. doi:10.1111/apt.13961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。